RxDoctor Payments Data

Geoffrey Jao, MD

Advanced Heart Failure and Transplant Cardiology · Scottsdale, AZNPI 1992885545

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (28.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Pfizer at 35.1% of the total. 2025 is the largest year on record at $8,073, more than ten times the $555 reported in 2019.

$21,382in general payments, 2019–2025

Across 112 payments — averaging $190.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • Abbott$7K
  • Alnylam Pharmaceuticals Inc.$3K
  • Abiomed$3K
  • Boston Scientific$269
  • BD$172
  • plus $619 from 11 others
$33,316in research payments, 2019–2025

Across 4 payments — averaging $8329.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$23K
  • Astrazeneca UK Limited$10K

What the payments were for

  • Consulting fees$3,62517%
  • Speaking & faculty fees$6,10029%
  • Travel & lodging$6,13029%
  • Food & beverage$5,52826%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$118,941
Medicare patients
376
Services billed
1,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis64$1,499,553
VyndaqelTafamidis Meglumine16$357,317
EntrestoSacubitril/Valsartan173$160,120
JardianceEmpagliflozin169$139,951
FarxigaDapagliflozin Propanediol147$114,651
EliquisApixaban46$30,117
Eplerenone24$2,060
Amiodarone Hcl32$1,790
Spironolactone301$1,645
Metoprolol Succinate184$1,619
Dutasteride31$651
Losartan Potassium103$491
Bumetanide29$440
Torsemide36$391
Digoxin36$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$7,497$1,886,987126 claims
AstraZenecaFarxiga$47$114,651147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →